|
1
|
Swerdllow S, Campo E and Harris NL: WHO
Classification of Tumours of Haematopoietic and Lymphoid Tissues.
4th. IARC Press; Lyon: 2008
|
|
2
|
Zuckerman T and Rowe JM: Pathogenesis and
prognostication in acute lymphoblastic leukemia. F1000Prime Rep.
6:592014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raetz EA and Bhatla T: Where do we stand
in the treatment of relapsed acute lymphoblastic leukemia?
Hematology. Am Soc Hematol Educ Program. 2012:129–136. 2012.
|
|
4
|
Litzow MR: Arsenic trioxide. Expert Opin
Pharmacother. 9:1773–1785. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
You D, Kim Y, Jang MJ, Lee C, Jeong IG,
Cho YM, Hwang JJ, Hong JH, Ahn H and Kim CS: KML001 induces
apoptosis and autophagic cell death in prostate cancer cells via
oxidative stress pathway. PLoS One. 10:e01375892015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yoon JS, Kim ES, Park BB, Choi JH, Won YW,
Kim S and Lee YY: Anti-leukemic effect of sodium metaarsenite
(KML001) in acute myeloid leukemia with breaking-down the
resistance of cytosine arabinoside. Int J Oncol. 46:1953–1962.
2015.PubMed/NCBI
|
|
7
|
Muenyi CS, Trivedi AP, Helm CW and States
JC: Cisplatin plus sodium arsenite and hyperthermia induces
pseudo-G1 associated apoptotic cell death in ovarian cancer cells.
Toxicol Sci. 139:74–82. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoon JS, Hwang DW, Kim ES, Kim JS, Kim S,
Chung HJ, Lee SK, Yi JH, Uhm J, Won YW, et al: Anti-tumoral effect
of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's
lymphoma: An in vitro and in vivo study. Invest New Drugs. 34:1–14.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grant WB and Garland CF: The association
of solar ultraviolet B (UVB) with reducing risk of cancer:
Multifactorial ecologic analysis of geographic variation in
age-adjusted cancer mortality rates. Anticancer Res. 26A:2687–2699.
2006.
|
|
10
|
Giovannucci E, Liu Y, Rimm EB, Hollis BW,
Fuchs CS, Stampfer MJ and Willett WC: Prospective study of
predictors of vitamin D status and cancer incidence and mortality
in men. J Natl Cancer Inst. 98:451–459. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Colston K, Colston MJ and Feldman D:
1,25-dihydroxyvitamin D3 and malignant melanoma: The presence of
receptors and inhibition of cell growth in culture. Endocrinology.
108:1083–1086. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyaura C, Abe E, Kuribayashi T, Tanaka H,
Konno K, Nishii Y and Suda T: 1α,25-Dihydroxyvitamin D3 induces
differentiation of human myeloid leukemia cells. Biochem Biophys
Res Commun. 102:937–943. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gardner JP, Zhang F, Uskokovic MR and
Studzinski GP: Vitamin D analog
25-(OH)-16,23E-Diene-26,27-hexafluoro-vitamin D3 induces
differentiation of HL60 cells with minimal effects on cellular
calcium homeostasis. J Cell Biochem. 63:500–512. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McCarthy DM, San Miguel JF, Freake HC,
Green PM, Zola H, Catovsky D and Goldman JM: 1,25-dihydroxyvitamin
D3 inhibits proliferation of human promyelocytic leukaemia (HL60)
cells and induces monocyte-macrophage differentiation in HL60 and
normal human bone marrow cells. Leuk Res. 7:51–55. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Zhang J and Studzinski GP: AKT
pathway is activated by 1, 25-dihydroxyvitamin D3 and participates
in its anti-apoptotic effect and cell cycle control in
differentiating HL60 cells. Cell Cycle. 5:447–451. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sergeev IN: Calcium as a mediator of
1,25-dihydroxyvitamin D3-induced apoptosis. J Steroid Biochem Mol
Biol 89–90. 419–425. 2004. View Article : Google Scholar
|
|
17
|
Petrich A, Kahl B, Bailey H, Kim K, Turman
N and Juckett M: Phase II study of doxercalciferol for the
treatment of myelodysplastic syndrome. Leuk Lymphoma. 49:57–61.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu G, Wilding G, Staab MJ, Horvath D,
Miller K, Dresen A, Alberti D, Arzoomanian R, Chappell R and Bailey
HH: Phase II study of 1α-hydroxyvitamin D(2) in the treatment of
advanced androgen-independent prostate cancer. Clin Cancer Res.
9:4077–4083. 2003.PubMed/NCBI
|
|
19
|
Chou T-C and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Castedo M, Perfettini J-L, Roumier T,
Andreau K, Medema R and Kroemer G: Cell death by mitotic
catastrophe: A molecular definition. Oncogene. 23:2825–2837. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Castedo M, Perfettini J-L, Roumier T,
Valent A, Raslova H, Yakushijin K, Horne D, Feunteun J, Lenoir G,
Medema R, et al: Mitotic catastrophe constitutes a special case of
apoptosis whose suppression entails aneuploidy. Oncogene.
23:4362–4370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Abbas T and Dutta A: p21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Taylor WR and Stark GR: Regulation of the
G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Woo SR, Ham Y, Kang W, Yang H, Kim S, Jin
J, Joo KM and Nam DH: KML001, a telomere-targeting drug, sensitizes
glioblastoma cells to temozolomide chemotherapy and radiotherapy
through DNA damage and apoptosis. BioMed Res Int. 2014:7474152014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gross A, McDonnell JM and Korsmeyer SJ:
BCL-2 family members and the mitochondria in apoptosis. Genes Dev.
13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guyton KZ, Kensler TW and Posner GH:
Cancer chemoprevention using natural vitamin D and synthetic
analogs. Annu Rev Pharmacol Toxicol. 41:421–442. 2001. View Article : Google Scholar : PubMed/NCBI
|
